MedTrace Logo

The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

NCT04229433 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-05-25

No results posted yet for this study

Summary

The study is a randomized, single-blind, placebo-controlled, multiple-dose escalation Phase I trials. 2 dose groups were designed, 12 subjects in each dose group.The drug was administered single dose and multiple doses.

Conditions

  • Thrombus

Interventions

DRUG

SHR2285 tablet

Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.

DRUG

Placebo

Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2020-11-08
Completion
2020-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229433 on ClinicalTrials.gov